Latest filing published 21 Oct 2019 for Avalo Therapeutics, Inc., €495k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -54.8%Entry US$15,552.00 · Close at T+365 US$7,027.20
- +30.2%Entry US$9,734.40 · Close at T+365 US$12,672.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Matthew Phillips V: trading record in brief
All filings by Matthew Phillips V on record concern Avalo Therapeutics, Inc. We count 3 filings; the first trade dates from 10 December 2018 and the latest from 23 August 2019.
Every open-market trade on record is a purchase: 2 purchases worth €2,559, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 1 share grant. 2019 to date brings 1 purchase and no sales.
Most recently, on 21 October 2019, the filings show a share grant worth €495k in Avalo Therapeutics, Inc. The clock since the last published purchase (11 June 2019) now reads 2,708 days. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Matthew Phillips V
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 512,500 shares@ US$1.0799.5% of flowCommon StockSEC:0001578563-19-000034:0
- 523 shares@ US$2.850.3% of flowCommon StockSEC:0001578563-19-000023:0Canonical exit: 8 Sept 2019 (T+90)
- 497 shares@ US$2.850.2% of flowCommon StockSEC:0001729197-18-000003:0Canonical exit: 10 Mar 2019 (T+90)
3 of 3 declarations
